Inhibition of galectin‐3 augments the antitumor efficacy of PD‐L1 blockade in non‐small‐cell lung cancer

Multiple clinical trials have shown that monoclonal antibodies (mAbs) against programmed death‐ligand 1 (PD‐1/PD‐L1) can benefit patients with lung cancer by increasing their progression‐free survival and overall survival. However, a significant proportion of patients do not respond to anti‐PD‐1/PD‐...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Hongxin, Liu, Pengfei, Zhang, Yan, Han, Lujun, Hu, Zhihui, Cai, Ziqi, Cai, Jianhui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7931229/
https://www.ncbi.nlm.nih.gov/pubmed/33455075
http://dx.doi.org/10.1002/2211-5463.13088

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7931229/
https://www.ncbi.nlm.nih.gov/pubmed/33455075
http://dx.doi.org/10.1002/2211-5463.13088

Ejemplares similares